29 March 2024
Regulatory information – adjusted fees for applications to EMA from 1 April 2024
The European Medicines Agency (EMA) is reminding applicants and holders of marketing authorizations that revised fees will be implemented for all applications, excluding pharmacovigilance procedures, starting from 1 April 2024.
Annually, the European Commission approves a regulation modifying the fees payable to the Agency, taking into account the inflation rate in the European Union from the preceding year.
For more information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Swissmedic: Haemovigilance Annual Report 2025
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
European Medicines Agency: Highlights of the September 2026 Management Board meeting